Abstract:Objective To evaluate serum human epididymis protein 4 (HE4) as a biomarker for ovarian cancer. Methods HE4 was determined by ELISA in ovarian cancer patients ( n = 82 ) , benign ovarian disease patients ( n = 26 ) and healthy controls ( n = 40) . Results The level of HE4 was significantly higher in ovarian cancer group(46. 6 pmol/L) than that in benign ovarian disease group(31. 5 pmol/L) and healthy control group(24.0 pmol/L) in premenopausal women ( U = 95. 5 and 100.0, P< 0. 01, respectively). The level of HE4 in ovarian cancer group( 139. 0 pmol/L) was also significantly higher than that in benign ovarian disease group(35.4 pmol/L) and in healthy control group (27.7 pmol/L) in postmenopausal patients ( U = 25. 0 and 49. 0, P < 0. 01 , respectively ). The receiver operation characteristic (ROC) analysis showed the cut-off value to discriminate cancer patients from controls in premenopausal women group was established at 35. 7 pmol/L for HE4 ( sensitivity 71. 4% ; specificity 80. 0% ) , while the corresponding cut-off value in postmenopausal women group was set at 54. 5 pmol/L ( sensitivity 87. 0% ; specificity 92. 9% ). The diagnostic efficacy of HE4 was higher than carbohydrate antigen 125 ( CA125). The high risk of malignancy group was defined as the ROMA value >3. 5% for premenopausal women and > 12. 5% for postmenopausal women. With the progression of ovarian carcinoma, the levels of HE4 as well as the sensitivity were increased. HE4 concentrations were higher in patients with lymph node metastasis than those without metastasis ( U = 34. 0 and 77. 0 in premenopausal and postmenopausal women, P < 0. 01 , respectively). Changes of HE4 concentrations were correlated with tumor response. Elevated levels of HE4 were found in recurrent disease patient, and the levels were decreased while the patients were sensitive to therapy. Conclusion HE4 determination is helpful in the diagnosis and prognosis of ovarian cancer.

Prognostic value of serum and tissue HE4 expression in ovarian cancer: a systematic review with meta-analysis of 90 studies

Diagnostic Performance of HE4 and ROMA among Chinese Women.

HE4 as a biomarker for ovarian and endometrial cancer management.

Prognostic Values of HE4 Expression in Patients with Cancer: a Meta-Analysis

Expression of Serum Human Epididymis Protein 4 in Epithelial Ovarian Cancer and Its Correlation with Prognosis

The Role of HE4 in Ovarian Cancer: Inhibiting Tumour Cell Proliferation and Metastasis.

Human Epididymis Protein 4 (He4) As A Serum Tumor Biomarker In Patients With Ovarian Carcinoma

Recent Insight about HE4 Role in Ovarian Cancer Oncogenesis

Relationship between human epididymal protein 4 and depth of tumor invasion, postoperative recurrence, and metastasis of epithelial epithelial ovarian cancer

HE4 As a Serum Biomarker for ROMA Prediction and Prognosis of Epithelial Ovarian Cancer

A Clinical Diagnostic Value Analysis of Serum CA125, CA199, and HE4 in Women with Early Ovarian Cancer: Systematic Review and Meta-Analysis

Effect of Human Epididymis Protein 4 Gene Silencing on the Malignant Phenotype in Ovarian Cancer.

Diagnostic Values in Ovarian Cancer with the Measurement of Serum Human Epididymis Secretory Protein 4 Combined with CA125 and Osteopontin

Studies on the Value of Human Epididymis Protein 4 in Patients with Ovarian Cancer

Diagnostic value of serum HE4 in endometrial cancer: a meta-analysis

Usefulness of Human Epididymis Protein 4 in Predicting Cytoreductive Surgical Outcomes for Advanced Ovarian Tubal and Peritoneal Carcinoma

Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors

Correlation analysis of serum HE4, CA125 and CA199 expression levels with ovarian cancer

Serum HE4 As a Useful Biomarker in Discriminating Ovarian Cancer from Benign Pelvic Disease

Analysis of the gene expression profile in response to human epididymis protein 4 in epithelial ovarian cancer cells

The value of serum CA125, HE4 and imaging examinations in detecting the recurrence of ;postoperative ovarian cancer